Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.47 |
| ▸ | ITGAV | P06756 | 4/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.46 |
| ▸ | MC4R | P32245 | 9/20 | 0.45 |
| ▸ | MC5R | P33032 | 9/20 | 0.45 |
| ▸ | MC3R | P41968 | 9/20 | 0.45 |
| ▸ | MC1R | Q01726 | 9/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29569086 | 0.94 | ITGB3 (0.49) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL14883291 | 0.93 | MC4R (0.49) | CACNA1BITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL24975502 | 0.93 | PIN1 (0.49) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL15853554 | 0.92 | MC4R (0.46) | CACNA1BITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL29568895 | 0.92 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL18968797 | 0.92 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL12315562 | 0.91 | ITGB3 (0.48) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL22872754 | 0.90 | ITGB3 (0.49) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL21475019 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL19605481 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGB1ITGA5ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170245976-A1 | IMPLANTABLE BIOREACTOR FOR DELIVERY OF PARACRINE FACTORS | UNIV JOHNS HOPKINS (US) | 2017-08-31 | — | — | US | disclosed |
| US-20150217030-A1 | METHOD FOR COATING A MEDICAL DEVICE WITH A CONFORMAL HYDROGEL | THE JOHNS HOPKINS UNIVERSITY | 2015-08-06 | — | — | US | disclosed |
| US-20120083767-A1 | IMPLANTABLE BIOREACTOR FOR DELIVERY OF PARACRINE FACTORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170245976-A1 | IMPLANTABLE BIOREACTOR FOR DELIVERY OF PARACRINE FACTORS | PGF, BMP2, FGF2 | CACNA1B 4017/4885ITGB3 1309/4885ITGAV 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.